Quality indicators as a tool in improving the introduction of new medicines

Basic and Clinical Pharmacology and Toxicology

Volumn 116, Issue 2, 2015, Pages 146-157

  Campbell, Stephen M ^a   Godman, Brian ^b,c,d   Diogene, Eduardo ^e   Fürst, Jurij ^f   Gustafsson, Lars L ^b   Macbride Stewart, Sean ^g   Malmström, Rickard E ^b   Pedersen, Hanne ^h   Selke, Gisbert ⁱ   Vlahović Palčevski, Vera ^j   van Woerkom, Menno ^k   Wong Rieger, Durhane ^l   Wettermark, Björn ^b,m  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Health Insurance Institute   (Slovenia)

^g NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^h WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

ⁱ Wissenschaftliches Institut der AOK WIdO   (Germany)

^j KBC RIJEKA   (Croatia)

^k Dutch Institute for Rational Use of Medicine   (Netherlands)

^l Institute for Optimizing Health Outcomes   (Canada)

^m STOCKHOLM COUNTY COUNCIL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BUDGET; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; DATA EXTRACTION; DRUG MONITORING; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); WORKLOAD; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY;

DRUG;

COST-BENEFIT ANALYSIS; HEALTH SERVICES ACCESSIBILITY; HUMANS; PHARMACEUTICAL PREPARATIONS; QUALITY INDICATORS, HEALTH CARE;

EID: 84921263859     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12295     Document Type: Article

References (103)

1. Drews J. Drug discovery: a historical perspective. Science 2000;287:1960-4.
2. Hanlon JT, Artz MB, Pieper CF, Lindblad CI, Sloane RJ, Ruby CM et al. Inappropriate medication use among frail elderly inpatients. Ann Pharmacother 2004;38:9-14.
3. Kesselheim AS, Avorn J. The most transformative drugs of the past 25 years: a survey of physicians. Nat Rev Drug Discov 2013;12:425-31.
4. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004;329:15-9.
5. Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J et al. Personalising health care: feasibility and future implications for all stakeholder groups. BMC Med 2013;11:179.
6. Holmes HM, Min LC, Yee M, Varadhan R, Basran J, Dale W et al. Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. Drugs Aging 2013;30:655-66.
7. Eichler H-G, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens B et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev 2011;10:495-506.
8. Article 3: Convention on human rights and biomedicine. http://conventions.coe.int/Treaty/en/Treaties/Html/164.htm (last accessed on 03 March 2014).
9. Malmström R, Godman B, Diogene E, Baumgärtel C, Bennie B, Bishop I et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs. Front Pharmacol 2013;4:39.
10. Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems - A Position Paper. Eur J Clin Pharmacol 2008;64:1137-8.
11. Wettermark B, Godman B, Eriksson C et al. Einführung neuer arzneimittel in europäische gesundheitssysteme. GGW 2010;10:24-34 (Introduction of new medicines into European healthcare systems).
12. Godman B, Paterson K, Malmstrom R et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res 2012;12:439-41.
13. OECD. Pharmaceutical expenditure, in OECD, Health at a Glance 2011: OECD Indicators, OECD Publishing. doi: [http://www.oecd-ilibrary.org/docserver/download/fulltext/8111101ec063.pdf?expires=1343281688&id=id&accname=guest&checksum=4D4F46B30255998AA81601571E18EE8F] (last accessed on 01 March 2014).
14. Garuoliene K, Alonderis T, Marcinkevičius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth 2011;17:1-4.
15. Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH; DURQUIM Scientific Committee. Indicators of prescribing quality in drug utilization research: report of a European meeting (DURQUIM, 13-15 May 2004). Eur J Clin Pharmacol 2005;60:831-4.
16. Wettermark B, Jacobsson B, Godman B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl Health Econ Health Policy 2009;7:1-11.
17. Roland M. Linking physicians' pay to the quality of care - a major experiment in the United Kingdom. N Engl J Med 2004;351:1448-54.
18. Wettermark B, Pehrsson Å, Juhasz-Haverinen M, Veg M, Edlert M, Törnwall-Bergendahl G et al. Financial incentives linked to self-assessment of prescribing patterns - a new approach for quality improvement of drug prescribing in primary care. Qual Prim Casre 2009;17:179-89.
19. Marshall MN, Shekelle PG, Leatherman S, Brook RH. The public release of performance data. What do we expect to gain? A review of the evidence. JAMA 2000;283:1866-74.
20. Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, Hasselstrom J et al. The "Wise List"- A comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108:224-33.
21. Campbell SM, Reeves D, Kontopantelis E, Sibbald B, Roland M. Impact of pay-for-performance on quality of English primary care: interrupted time series analysis. N Engl J Med 2009;361:368-78.
22. Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Braspenning J, Wolffenbuttel BH, Denig P. A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiol Drug Saf 2010;19:319-34.
23. Coenen S, Ferech M, Haaijer-Ruskamp FM, Butler CC, Van der Stichele RH, Verheij TJ et al. European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. Qual Saf Health Care 2007;16:440-5.
24. Avery AJ, Dex G, Mulvaney G, Serumaga B, Spencer R, Lester H, Campbell SM. Development of prescribing -safety indicators for GPs using the RAND Appropriateness Method. Br J Gen Pract 2011;6:e526-36.
25. Wettermark B, Persson ME, Wilking N, Kalin M, Korkmaz S, Hjemdahl P et al. Forecasting drug use and expenditures in a metropolitan health region. BMC Health Serv Res 2010;10:12.
26. Evaluate Pharma. Surveying Tomorrow's BioPharma Landscape - The NASDAQ Biotech Index Up Close. Evaluate Pharma June 2012. [http://info.evaluatepharma.com/rs/evaluatepharmaltd/images/EvaluatePharma_NBI_Up_Close_2012.pdf] (last accessed on 26 February, 2014).
27. Godman B. Editorial - Health authority perspective on biosimilars. GaBI 2013;2(1):10-11.
28. Campbell SM, Braspenning J, Hutchinson A, Marshall MN. Research methods used in developing and applying quality indicators in primary care. BMJ 2003;326:816-9.
29. Lawrence M, Olesen F et al. Indicators of quality health care. Eur J Gen Pract 1997;3:103-8.
30. Donabedian A.Explorations in Quality Assessment and Monitoring. Vol. 1. The Definition of Quality and Approaches to its Assessment. Health Administration Press, Ann Arbor, Mich, 1980.
31. Campbell SM, Roland MO, Buetow SA. Defining quality of care. Soc Sci Med 2000;51:1611-25.
32. Campbell SM, Kontopantelis E, Hannon KL, Barber A, Burke M, Lester HE. Framework and indicator testing protocol for developing and piloting quality indicators for the UK Quality and Outcomes Framework. BMC Fam Pract 2011;12:85.
33. Pencheon D: The Good Indicators Guide: Understanding how to use and choose indicators. Institute for Innovation and Improvement, London, 2008: [http://www.apho.org.uk/resource/item.aspx?RID=44584] (last accessed on 01 March 2014).
34. HEDIS. Technical Specifications for Physician Measurement. NCQA, Washington DC, 2009.
35. Braspenning J, Hermans R, Calsbeek H, Westert G, Campbell S, Grol R. Quality & safety of care, In: Grol R et al. (eds). Improving Patient Care: Implementation of Change, 2nd Edn. Elsevier, Amsterdam, 2013
36. Ferlie EB, Shortell SM. Improving the quality of health care in the United Kingdom and the United States: a framework for change. Milbank Q 2001;79:281-315.
37. World Bank. Human resources are vital. 2013 [http://web.worldbank.org/WBSITE/EXTERNAL/TOPICS/EXTHEALTHNUTRITIONANDPOPULATION/EXTHSD/0,print:Y~isCURL:Y~contentMDK:20190580~menuPK:438351~pagePK:148956~piPK:216618~theSitePK:376793~isCURL:Y, 00.html] (last accessed on 02 February 2014).
38. Godman B, Campbell S, Suh HS, Finlayson AE, Bennie M, Gustafsson LL. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J Health Tech Assess 2013;1:27-42.
39. Godman B, Shrank W, Andersen M, Berg C et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol 2011;1:1-16.
40. Joppi R, Cinconze E, Mezzalira L, Pase D, Poggiani C, Rossi E. Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur J Intern Med 2013;24:318-23.
41. Troncoso A, Diogène E. Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs. Eur J Clin Pharmacol 2014;70:249-50.
42. Godman B, Malmström RE, Diogene E, Jayathissa S, McTaggart S, Alvarez-Madrazo S et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimise the utilisation of new drugs. Front Pharmacol 2014;5:109.
43. Editorial. New drugs and indications in 2011. France is better focused on patients' interests after the Mediator scandal, but stagnation elsewhere. Prescrire Int 2012;21:106-7.
44. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol 2013;31:3600-4.
45. Kaplan WWV, Mantel-Teeuwisse A, Stolk P, Duthey B, Laing R. Priority Medicines for Europe and the World 2013 Update Report. 2013. http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf?ua=1 (last accessed on 02 March 2014).
46. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010;10:153.
47. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: The European experience. LSE 2013. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf (last accessed on 04 March 2014).
48. Wettermark B. The intriguing future of pharmacoepidemiology. Eur J Clin Pharmacol 2013;69(Suppl 1):43-51.
49. World Health Organization (WHO). Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330) http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf
50. Liu Y, Si M, Tang L, Shangguan S, Wu H, Li J et al. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors. Bioorg Med Chem 2013;pii:S0968-0896(13)00655-X.
51. Singh BN, Connolly SJ, Crijns H, Roy D, Kowey PR, Capucci A et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357(10):987-99.
52. Wettermark B, Godman B, Neovius M, Hedberg T, Mellgren T, Kahan T et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 2010;94:221-9.
53. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation [Internet]. 2012. 6, Conclusions. http://www.ncbi.nlm.nih.gov/books/NBK169801/ (last accessed on 26 February 2014).
54. Hallas J, Stovring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 2006;98:260-5.
55. Andersen M. Is it possible to measure prescribing quality using only prescription data? Basic Clin Pharmacol Toxicol 2006;98:314-9.
56. Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012;35:647-62.
57. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87.
58. Björkhem-Bergman J, Andersen-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013;69(Suppl 1):73-8.
59. IQWIG. Telaprevir: Added benefit in certain patients with hepatitis C. https://www.iqwig.de/en/press/press_releases/press_releases/telaprevir_added_benefit_in_certain_patients_with_hepatitis_c.2450.html (last accessed on 25 February 2014)
60. IQWIG. Boceprevir: Indication of added benefit for specific patients. https://www.iqwig.de/en/press/press_releases/press_releases/boceprevir_indication_of_added_benefit_for_specific_patients.2236.html (last accessed on 25 February 2014)
61. Bierman AS, Clark JP. Performance measurement and equity. Br Med J 2007;334:1333-4.
62. Neovius M, Sundström A, Simard J, Wettermark B, Cars T, Feltelius N et al. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol 2011;40:8-15.
63. Packer C, Simpson S, Stevens A. EuroScan: the European Information Network on New and Changing Health Technologies. International diffusion of new health technologies: a ten-country analysis of six health technologies. Int J Technol Assess Health Care 2006;22:419-28.
64. Gillström A, Wettermark B. For the Scientific Committee of the ISPE/EuroDurg meeting in Antwerp 2011. Literature Review. Cross-national comparison of DU activities. Publication from the European scientific meeting of Drug Utilization "Better public health through pharmacoepidemiology and quality use of medicine", Antwerp, Belgium 2011.
65. Adams AS, Soumerai SB, Lomas J, Ross-Degnan D. Evidence of self-report bias in assessing adherence to guidelines. Int J Qual Health Care 1999;11:187-92.
66. Wettermark B, Zoëga H, Furu K, Korhonen M, Hallas J, Nørgaard M et al. The Nordic prescription databases as a resource for pharmacoepidemiological research-a literature review. Pharmacoepidemiol Drug Saf 2013;22:691-9.
67. Cars T, Wettermark B, Malmström RE, Ekeving G, Vikström B, Bergman U et al. Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model. Basic Clin Pharmacol Toxicol 2013;112:392-400.
68. Vandenberghe HE, Van Casteren V, Jonckheer P, Bastiaens H, Van der Heyden J, Lafontaine MF et al. Collecting information on the quality of prescribing in primary care using semi-automatic data extraction from GPs' electronic medical records. Int J Med Inform 2005;74:367-76.
69. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000;17:501-13.
70. van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy 2014;12:33-40.
71. Mauskopf SA, Earnshaw S, Daniel Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res 2005;5:65-79.
72. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL: Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. Oxford University Press, Oxford, 2005.
73. Sorensen SV, Peng S, Monz BU, Bradley-Kennedy C, Kansal AR. A comparative analysis of models used to evaluate the cost-effectiveness of Dabigatran versus Warfarin for the prevention of stroke in atrial fibrillation. Pharmacoeconomics 2013;31:589-604.
74. McDonald R, Harrison S, Checkland K, Campbell SM, Roland MO. Impact of financial incentives on clinical autonomy and internal motivation in primary care. Br Med J 2007;334:1333-4.
75. Spooner A, Chapple A, Roland M. Impact of financial incentives on clinical autonomy and internal motivation in primary care: ethnographic study. J Health Serv Res Policy 2001;6:145-50.
76. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
77. Lecluse LL, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for psoriasis and the European "Psonet" initiative. Dermatology 2009;218:347-56 72a and 72b.
78. van Dartel SA, Fransen J, Kievit W, Dutmer EA, Brus HL, Houtman NM et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2013;52:1052-7.
79. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012;39:1179-84.
80. Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ 2011;343:d5621.
81. Campbell SM, Eriksson T. Multiple strategies for quality improvement and patient safety - money alone is not the answer, nor is trust. Eur J Gen Pract 2011;17:238-40.
82. Finlayson AE, Godman B, Aston E, Gustafsson LL, Ali R. Personalizing healthcare: from genetics through payment to improving care? J R Soc Med 2013;106:41-4.
83. Doran T, Kontopantelis E, Valderas J, Campbell SM, Roland MO, Salisbury C et al. The effect of financial incentives on incentivized and non-incentivized clinical activities. Evidence from the UK's Quality and Outcomes Framework. Br Med J 2011;342:d3590.
84. Pedersen N, Elkjaer M, Duricova D, Burisch J, Dobrzanski C, Andersen NN et al. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease. Aliment Pharmacol Ther 2012;36:840-9.
85. Collier J. Price of independence. BMJ 2006;332:1447-9.
86. Gordon K, Smith F, Dhillon S. Effective chronic disease management: patients' perspectives on medication-related problems. Patient Educ Couns 2007;65:407-15.
87. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm 2008;14:553-60.
88. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206.
89. Kripalani S, Henderson LE, Jacobson TA, Vaccarino V. Medication use among inner-city patients after hospital discharge: patient-reported barriers and solutions. Mayo Clin Proc 2008;83:529-35.
90. Furlow B. Patient reported outcomes are changing drug trials and clinical oncology. Chemotherapy advisor. http://www.chemotherapyadvisor.com/patient-reported-outcomes-are-changing-drug-trials-and-clinical-oncology/article/309426/ (last accessed on 25 February 2014)
91. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011;86:304-14.
92. Mitchell AJ, Selmes T. Why don't patients take their medicine? Reasons and solutions in psychiatry. Adv Psychiatr Treat 2007;13:336-46.
93. Cobden DS, Niessen LW, Barr CE, Rutten FF, Redekop WK. Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in Type 2 diabetes. Value Health 2010;13:138-47.
94. Thomas K. Study of drug for blood clots caused a stir, records show. New York Times.www.nytimes.com/2014/02/06/business/study-of-blood-clot-drug-pradaxa-unnerved-its-maker-documents-suggest.html (last accessed on 02 March 2014).
95. Lansky D, Milstein A. Quality measurement in orthopaedics: the purchasers' view. Clin Orthop Relat Res 2009;467:2548-55.
96. Rose J. Industry influence in the creation of pay-for-performance quality measures. Qual Manag Health Care 2008;17:27-34.
97. Lester HE, Hannon KL, Campbell SM. Identifying unintended consequences of quality indicators: a qualitative study. BMJ Qual Saf 2011;20:1057-61.
98. Kung J, Miller RR, Mackowiak PA. Failure of clinical practice guidelines to meet Institute of medicine standards: two more decades of little, if any, progress. Arch Intern Med 2012;172:1628-33.
99. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf, Eikelboom JW et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol 2014;63:321-8.
100. Kaiser J. New cystic fibrosis drug offers hope, at a price. Science 2012;335:645.
101. Experts in chronic myeloid leukemia. Price of drugs for chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML Experts. Blood 2013;121(22):4439-42.
102. Cohen J, Felix A. Are payers treating orphan drugs differently? Journal of Market Access & Health Policy. 2014;2:23513 - http://dx.doi.org/10.3402/jmahp.v2.23513.
103. Campbell SM, Scott A, Parker R, Naccarella L, Furler JS, Young D et al. Implementing pay-for-performance in Australian primary care: lessons from the United Kingdom and the United States. Med J Aust 2010;193:408-11.